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OBJECTIVES We examined whether oral administration of L-arginine, the substrate for nitric oxide (NO)
synthesis, increases NO bioactivity in healthy postmenopausal women.
BACKGROUND Nitric oxide may protect arteries against atherosclerosis, as suggested by experimental studies
in animals. Estrogen therapy, which has been shown to increase NO bioactivity in the
vasculature of healthy postmenopausal women, is not acceptable for long-term use by many
women.
METHODS In a randomized, double-blind, crossover study, 10 postmenopausal women without addi-
tional risk factors for atherosclerosis received L-arginine 9 g or placebo daily for one month,
with treatment periods separated by one month. Nitric oxide levels in serum (as an index of
endothelial NO release), brachial artery endothelium-dependent dilator responses to hyper-
emia by ultrasonography (as an index of vascular NO bioactivity) and markers of inflamma-
tion in blood that are inhibited by NO in cell culture experiments were measured at the end
of each treatment period.
RESULTS L-arginine levels in plasma were increased in all women during L-arginine treatment
compared with placebo (136.8 6 63.1 vs. 75.2 6 16.2 mmol/liter, p 5 0.009). However, there
was no change in serum nitrogen oxide levels (42.1 6 24.5 vs. 39.1 6 16.6 mmol/liter, p 5
0.61), nor was there an effect of L-arginine on flow-mediated dilation during hyperemia
(3.8 6 3.0% vs. 4.9 6 4.8%, p 5 0.53) compared with placebo. Our study had sufficient
power (b 5 0.80) to detect a true absolute treatment difference in flow-mediated brachial
artery dilation of 1.7% or larger as statistically significant at alpha 5 0.05. There was no effect
of L-arginine on serum levels of soluble cell adhesion molecules compared with placebo:
E-selectin (50.6 6 14.8 vs. 52.1 6 17.0 ng/ml, p 5 0.45), intercellular adhesion molecule-1
(230 6 51 vs. 230 6 52 ng/ml, p 5 0.97) and vascular cell adhesion molecule-1 (456 6 62
vs. 469 6 91 ng/ml, p 5 0.53).
CONCLUSIONS Oral administration of L-arginine may not augment endothelial NO synthesis and release in
postmenopausal women and is thus unlikely to be of general benefit to healthy postmeno-
pausal women in protection from the development of atherosclerosis. (J Am Coll Cardiol
2000;35:271–6) © 2000 by the American College of Cardiology
Nitric oxide (NO), an important regulator of vascular
homeostasis, is synthesized continuously in endothelial cells
by the constitutive enzyme nitric oxide synthase (NOS III)
from the substrate L-arginine (1). Normally, L-arginine is
not rate-limiting in this reaction; the Km for NOS is in the
micromolar range, whereas intracellular levels of arginine
are in the millimolar range. Under certain conditions,
however, L-arginine administration can enhance the syn-
thesis of NO. In the hypercholesterolemic rabbit model,
dietary supplementation with L-arginine reduced atheroma
formation, improved endothelium-dependent dilation (2,3),
decreased platelet aggregation (4) and decreased monocyte
adherence to aortic endothelium (5). In hypercholester-
olemic humans, intravenous or oral L-arginine improved
endothelium-dependent dilation of forearm vasculature
(6,7). L-arginine has also been shown (in vitro) to reduce
human monocyte adhesion to endothelial cells and decrease
expression of endothelial cell adhesion molecules (8).
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Estrogen therapy improves vascular NO bioactivity in the
coronary and systemic circulations of postmenopausal
women (9–13), but it is unacceptable for long-term use by
many because of side effects and concerns regarding cancer
risk. Based on experimental studies and the limited human
experience to date, we reasoned that L-arginine may also
increase NO bioactivity in postmenopausal women. Ac-
cordingly, we measured the effects of L-arginine on vascular
NO bioactivity and on markers of inflammation potentially
affected by NO in postmenopausal women in a randomized,
double-blind, placebo-controlled study.
METHODS
Study population and design. Twelve healthy postmeno-
pausal women (55 6 5 years) who had not taken hormone
replacement, antioxidant vitamin (A, C, E) or lipid-
lowering therapies in the preceding two months were
enrolled in the study. All had plasma 17b-estradiol levels
below 50 pg/ml and follicle stimulating hormone levels .50
pg/ml. No subject was hypertensive, diabetic or a current
cigarette smoker. The baseline lipid profile was as follows:
total cholesterol, 199 6 22 (range, 171 to 222) mg/dl;
low-density lipoprotein cholesterol, 124 6 22 (range, 78 to
152) mg/dl; high-density lipoprotein cholesterol, 60 6 9
(range, 46 to 76) mg/dl; and triglycerides, 97 6 49 (range,
48 to 187) mg/dl. Treatment with all nonsteroidal anti-
inflammatory agents (including aspirin) was discontinued
during the study. Women were randomly assigned to
L-arginine 9 g (3 g in 500-mg capsules three times a day) or
identical placebo capsules daily, with each treatment period
one month in duration and separated by one-month off
treatment. All study participants returned to the Clinical
Center for blood drawing and brachial artery reactivity
measurements at the end of each treatment period. Subjects
were placed on a nitrate-restricted diet (#15 mg/day) for
three days before each visit in order to reduce the contri-
bution of dietary nitrates to serum nitrogen oxide levels (14).
The study was approved by the Institutional Review Board
of the National Heart, Lung, and Blood Institute, and all
participants gave written, informed consent. One woman
stopped the study during the first treatment period (placebo)
because of abdominal pain, and one woman was excluded
from further participation after completing the first treat-
ment period (L-arginine) because of bullous pemphigoid
that required steroid treatment. Thus, 10 women completed
both phases of the study and serve as the source of data for
this report.
Laboratory assays. Blood samples for laboratory assays
were obtained between 8 and 9 AM following overnight
fasting and immediately coded, so that investigators per-
forming laboratory assays would be blinded to subject
identity or study sequence. Plasma and serum were sepa-
rated by centrifugation and stored at 280°C until analysis.
C-reactive protein (CRP) in the serum was measured by a
fluorescence polarization immunoassay (TdxFLEX Ana-
lyzer, Abbott, Abbott Park, Illinois). L-arginine was quan-
titated in plasma by high-pressure liquid chromatography
(at Mayo Medical Laboratories, Rochester, Minnesota).
Serum nitrogen oxide (nitrate/nitrite) levels were measured
by conversion of nitrate to nitrite by nitrate reductase,
followed by addition of Griess reagents and photometric
measurement of absorbance (Oxford Biomedical Research,
Oxford, Michigan). E-selectin, intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) levels were measured by enzyme-
linked immunosorbent assays (R&D Systems, Inc., Minne-
apolis, Minnesota).
Blood samples for flow cytometry were processed using
the Coulter Q Prep workstation (Beckman Coulter Corp.,
Miami, Florida). Expression of the following integrin ad-
hesion molecules was measured on monocytes, lymphocytes
and granulocytes: 1) LFA-1 (CD11a); 2) Mac-1 (CD11b);
and 3) VLA-4 (CD49d), and the selectin adhesion molecule
L-selectin (CD62L) (15). All monoclonal antibodies to cell
surface adhesion molecules were directly conjugated to
fluorescein isothiocyanate (FITC) and were obtained from
Immunotech (Beckman Coulter Company, Miami, Flori-
da). Flow cytometry was performed by the EPICS XL-
MCL Flow Cytometer (Beckman Coulter Company)
equipped with a 15-mW, 488-nm argon ion laser. A total of
at least 50,000 events per sample were analyzed. The
lymphocytes, monocytes and granulocytes were electroni-
cally isolated by collection of a dual-parameter histogram of
log 90° light scatter versus forward angle light scatter.
Fluorescence intensity of the measured adhesion molecule
was expressed as mean channel units. Relative FITC log
fluorescence was calculated using the histogram data. Flow
cytometry settings remained constant for all data generated,
and standard beads were used to calibrate the instrument.
Vascular studies. Imaging studies of the left brachial artery
were performed using a high-resolution ultrasound 7.5-
MHz linear-array transducer (Hewlett-Packard) following
30 min of rest, based on the technique reported by Celer-
majer et al. (16). After finding the clearest view of the
brachial artery, the skin was marked and the arm kept in the
same position throughout the study. Baseline measurements
included brachial artery diameter and flow velocity mea-
sured by pulsed-Doppler with the range gate (1.5 mm) in
the center of the artery. The system permitted a direct
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assessment of the angle between the bloodstream and the
intersecting ultrasound beam, which was then used to
calculate blood flow velocity. Endothelium-dependent va-
sodilation was assessed by measuring the change in diameter
of the brachial artery during reactive hyperemia created by
an inflated cuff (250 mm Hg for 5 min) on the forearm, a
response previously shown to be mediated primarily by NO
(17). After cuff deflation, flow velocity was measured for the
first 15 s, then the arterial diameter was recorded continually
for the next 60 s. Fifteen minutes later, repeat baseline
diameter and flow velocity measurements were made, fol-
lowed by nitroglycerin spray (0.4 mg) under the tongue to
assess endothelium-independent vasodilation. Three min-
utes later, arterial diameter and flow velocity measurements
were recorded. Arterial diameter was measured in millime-
ters from the intima-blood interface on both the anterior
and posterior walls, coincident with the R wave on the
ECG, at two sites along the artery and for three cardiac
cycles, with these six measurements averaged. During hy-
peremia, six measurements of arterial diameter were aver-
aged during maximum dilation between 50 and 70 s
following cuff deflation. Blood flow was calculated by
multiplying the velocity-time integral of the Doppler flow
signal by the heart rate and the cross-sectional area of the
vessel.
Reproducibility of study parameters. In a recently com-
pleted study of 28 healthy postmenopausal women who
underwent studies off all hormone and other therapies on
three occasions (18), each separated by 12 weeks, coeffi-
cients of variation for study parameters were computed as
the square root of the pooled within-subject variance di-
vided by the mean of the averages over all subjects for each
parameter: flow-mediated brachial artery dilation 5 0.623;
nitrogen oxides 5 0.365; E-selectin 5 0.226, ICAM-1 5
0.159, VCAM-1 5 0.178.
Statistical analysis. Measurements are expressed as
mean 6 SD. The two-sided paired Student t test was used
to compare changes in vascular responses and laboratory
values between L-arginine and placebo treatments, with
p , 0.05 an indicator of statistical significance. The primary
study comparison predefined in advance of data collection
was flow-mediated dilation of the brachial artery with
L-arginine treatment compared with placebo. All other
comparisons were regarded as secondary, and no adjust-
ments to p values for multiple comparisons were performed.
RESULTS
Effects of L-arginine on vasomotor function. L-arginine
treatment for one month nearly doubled serum L-arginine
levels compared with placebo treatment (136.8 6 63.1 vs.
75.2 6 16.2 mmol/liter, p 5 0.009). Despite the signifi-
cantly higher L-arginine levels following one month of
L-arginine treatment, there was no significant change in
serum nitrogen oxide levels compared with placebo treat-
ment (42.1 6 24.5 vs. 39.1 6 16.6 mmol/liter, p 5 0.61).
There was no significant effect of L-arginine treatment on
brachial artery diameters, flow, flow-mediated dilation with
hyperemia or nitroglycerin-induced dilation compared with
placebo treatment (Table 1, Fig. 1). In our study of 10
women, we could detect a true treatment difference in
flow-mediated dilation (primary end point) of 1.7% or
larger between L-arginine and placebo treatment as statis-
tically significant with a two-sided paired t test at alpha 5
0.05 and 80% power. We observed a 1.1% absolute differ-
ence in flow-mediated dilation between the two treatments
(from 3.8% to 4.9%), with the dilation actually being greater
during placebo treatment.
Effects of L-arginine on markers of inflammation. There
was no effect of L-arginine treatment on serum levels of
markers of inflammation compared with placebo treatment:
E-selectin, 50.6 6 14.8 vs. 52.1 6 17.0 ng/ml, p 5 0.45;
ICAM-1, 230 6 51 vs. 230 6 52 ng/ml, p 5 0.97;
VCAM-1, 456 6 62 vs. 469 6 91 ng/ml, p 5 0.53; and
CRP, 0.5 6 0.8 vs. 0.5 6 0.7 mg/dl, p 5 0.9. Flow
cytometry measurements for all adhesion molecules on
monocytes, lymphocytes and granulocytes are provided in
Table 2. L-arginine treatment was associated with a change
in levels only with Mac-1 on monocytes, with a decreased







Basal 3.25 6 0.06 3.25 6 0.05 1
Hyperemia 3.38 6 0.07 3.41 6 0.06 0.82
Brachial artery
flow (ml/min)
Basal 79 6 72 79 6 36 0.99
Hyperemia 399 6 155 388 6 168 0.89
Data 5 mean 6 SD.
Figure 1. Bar graphs show percent increase in brachial artery
diameter from baseline measurements following forearm ischemia
(flow-mediated dilation) in the left panel, and following nitro-
glycerin administration in the right panel. Data 5 mean 6 SEM.
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expression compared with placebo treatment (12.7 6 5.7 vs.
17.4 6 6.4 mean fluorescence units, p 5 0.015).
DISCUSSION
Studies in humans and in animals have shown that acute
infusion and oral administration of L-arginine improve
endothelium-dependent vasorelaxation of arteries with pre-
viously impaired dilator responses, and in animal models,
protect against diet-induced atherosclerosis (2–7). We and
others have shown previously that the acute infusion and
oral administration of estrogen to postmenopausal women
improve endothelium-dependent vasodilation of the coro-
nary and systemic circulations (9–13). In this regard,
flow-mediated dilation in our subjects receiving placebo was
similar to the placebo or pretreatment measurements in two
studies, both of which showed a doubling of this response
after oral estrogen treatment (11,12). We previously found
that enhancement by estrogen of acetylcholine-stimulated
vasodilation in the coronary circulation was inhibited by
NG-monomethyl-L-arginine (L-NMMA) (13), a compet-
itive inhibitor of NOS (19). Further, flow-mediated dilation
of the brachial artery is largely inhibited by L-NMMA (17).
These observations suggest that estrogen enhances NO
bioactivity either through increased synthesis or protection
from oxidative degradation.
We reasoned that long-term administration of the sub-
strate for NO synthesis might accomplish the same effects as
estrogen on endothelium-dependent vasodilation. Such a
finding could be of considerable interest to postmenopausal
women at risk for atherosclerosis, but who cannot or choose
not to take estrogen therapy because of concerns regarding
side effects and cancer risk. However, in contrast to the
robust effects of estrogen and statin lipid-lowering therapies
on brachial artery flow-mediated dilation in healthy post-
menopausal women (11,12), L-arginine treatment (9 g daily
for one month) did not augment nitrogen oxide levels in
serum, and did not improve endothelium-dependent vaso-
dilation, as compared with placebo treatment in our post-
menopausal study participants.
Because NO donors have been shown in endothelial cell
culture experiments to prevent activation of proinflamma-
tory genes by inhibition of an important nuclear transcrip-
tion factor (NFkB) (20–23), we measured the effect of
L-arginine on soluble cell adhesion molecules. Cell adhe-
sion molecules, once expressed on the surfaces of endothelial
cell or leukocytes in culture following cytokine stimulation,
are shed into the supernatant within 24 h and are measur-
able in the sera of humans using the same immunoassay
(24–26). Levels of VCAM-1, ICAM-1, E-selectin and
L-selectin are increased in sera from patients with athero-
sclerosis (27–31). However, L-arginine did not reduce levels
of cell adhesion molecules in our postmenopausal subjects as
compared with placebo treatment. This contrasts with
estrogen treatment, which reduced levels of cell adhesion
molecules in sera of healthy and hypercholesterolemic post-
menopausal women (12,18,32).
We reasoned that if L-arginine suppressed inflammatory
cytokine expression by vascular cells as a result of increased
NO, then the expression of leukocyte integrin and selectin
adhesion molecules, the counter-ligands to cell adhesion
molecules on the vascular endothelium, might also be
reduced. Mac-1 expression on monocytes, as measured by
flow cytometry, was significantly lowered with L-arginine
treatment relative to placebo. However, L-arginine had no
effect on Mac-1 integrin expression on other leukocyte cell
lines, nor on the other leukocyte integrins and selectin
adhesion molecule expression, raising the possibility that the
change in Mac-1 expression was due to chance.
Study limitations. A possible explanation for failure to
demonstrate a vascular effect of L-arginine is that the dose
used (9 g daily) in our study was insufficient. However,
higher doses have been associated with side effects of
nausea, stomach cramps and diarrhea (7). Further, in this
study of hypercholesterolemic subjects, administration of










L-arginine 20.2 6 10.2 12.7 6 5.7 6.7 6 3.7 5.9 6 1.5
Placebo 19.2 6 10.4 17.4 6 6.4 7.5 6 3.9 5.7 6 0.8
p value 0.60 0.015 0.36 0.73
Lymphocytes
L-arginine 10.08 6 4.0 0.68 6 0.14 4.15 6 2.05 3.79 6 1.10
Placebo 9.69 6 6.1 0.69 6 0.22 4.68 6 1.88 3.73 6 0.85
p value 0.88 0.89 0.18 0.72
Granulocytes
L-arginine 10.48 6 2.17 14.97 6 4.86 16.15 6 5.46 2.09 6 0.81
Placebo 9.17 6 1.70 14.97 6 4.34 16.17 6 5.06 1.68 6 0.42
p value 0.13 0.99 0.98 0.25
Data 5 mean 6 SD. mfu 5 mean fluorescence units.
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L-arginine 21 g daily caused the same relative increase in
serum L-arginine levels as was seen in our study with 9 g
daily for the same duration of administration. A second
potential limitation of our study is the relatively small
number of participants. However, our study had sufficient
power (80%) to detect an absolute improvement in flow-
mediated brachial artery dilation of 1.7%, which is less than
the 4% to 5% absolute improvement in flow-mediated
dilation observed with estrogen treatment in healthy post-
menopausal women (11,12,18). Indeed, flow-mediated di-
lation was actually greater while receiving placebo in our
study, decreasing the likelihood that a larger number of
subjects might have shown benefit from L-arginine treat-
ment. The coefficients of variations for the parameters
measured in our study are sufficiently low that an inability to
show L-arginine treatment benefit due to poor measure-
ment reproducibility over time seems unlikely. A third
potential limitation of the study is that brachial artery
endothelial function could have been normal in our study
participants, and thus unlikely to be improved by
L-arginine, similar to the absence of L-arginine effect in
healthy young men given L-arginine 21 g daily for three
days (33). In this regard, oral L-arginine 21 g daily for one
month significantly improved brachial artery flow-mediated
dilator responsiveness in 27 young hypercholesterolemic
men and women in a randomized, double-blind, placebo-
controlled study (7). However, we have recently shown that
estrogen and vitamin E, alone and in combination, improve
endothelium-dependent brachial artery responsiveness in
healthy postmenopausal women with similar magnitude of
brachial artery flow-mediated dilation without therapy as
was measured in our study participants during the placebo
phase (18). A fourth potential limitation of our study is that
levels of asymmetric dimethylarginine (ADMA) were not
measured in the plasma of our participants. Miyazaki and
coworkers (34) reported elevated levels of this competitive
inhibitor of NOS in patients with risk factors for athero-
sclerosis. Thus, it is possible that had levels of ADMA been
found to be low in our patients, improvement in endothelial
function with L-arginine would not have been expected.
However, given the current interest in L-arginine as a
therapeutic supplement to prevent atherosclerosis, our study
suggests that L-arginine may not benefit the general pop-
ulation of healthy postmenopausal women.
In conclusion, we did not find evidence that L-arginine,
when administered for one month to healthy postmeno-
pausal women, augments endothelial NO synthesis and
release or lower soluble cell adhesion molecule levels in
contrast to the effects of estrogen therapy. Thus, our study
suggests that L-arginine is unlikely to be of general benefit
to healthy postmenopausal women in protection from the
development of atherosclerosis.
Acknowledgments
We appreciate the assistance of Maureen Leser, RD, for
preparing the low-nitrate diet, Rene Costello, MT, for his
excellent technical assistance, and Toni Julia for typing the
manuscript.
Reprint requests and correspondence: Dr. Richard O. Cannon,
National Institutes of Health, Building 10, Room 7B15, 10 Center
Drive MSC-1650, Bethesda, Maryland 20892-1650. E-mail:
cannonr@nih.gov.
REFERENCES
1. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for
the biological activity of endothelium-derived relaxing factor. Nature
1987;327:524–6.
2. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME.
Antiatherogenic effects of L-arginine in the hypercholesterolemic
rabbit. J Clin Invest 1992;90:1168–72.
3. Boger RH, Bode-Boger SM, Mugge A, et al. Supplementation of
hypercholesterolemic rabbits with L-arginine reduces the vascular
release of superoxide anions and restores NO production. Atheroscle-
rosis 1995;117:273–84.
4. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP. L-arginine
attenuates platelet reactivity in hypercholesterolemic rabbits. Arterio-
scler Thromb 1994;14:1529–33.
5. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke IP. Enhanced
endothelial adhesiveness in hypercholesterolemia is attenuated by
L-arginine. Circulation 1994;89:2176–82.
6. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke
JP. L-arginine improves endothelium-dependent vasodilation in hy-
percholesterolemic humans. J Clin Invest 1992;90:1248–53.
7. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves
endothelium-dependent dilation in hypercholesterolemic young
adults. J Clin Invest 1996;97:1889–94.
8. Adams MR, Jessup W, Hailstones D, Celermajer D. L-arginine
reduces human monocyte adhesion to vascular endothelium and
endothelial expression of cell adhesion molecules. Circulation 1997;
95:662–8.
9. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological
levels of estrogen on coronary vasomotor function in postmenopausal
women. Circulation 1994;89:2545–51.
10. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III.
Acute vascular effects of estrogen in postmenopausal women. Circu-
lation 1994;90:786–91.
11. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves
endothelium-dependent, flow-mediated vasodilation in postmeno-
pausal women. Ann Intern Med 1994;121:936–41.
12. Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and
cholesterol-lowering therapies in hypercholesterolemic postmeno-
pausal women. Circulation 1999;99:354–60.
13. Guetta V, Quyyumi AA, Prasad A, Panza JA, Waclawiw M, Cannon
RO III. The role of nitric oxide in coronary vascular effects of estrogen
in postmenopausal women. Circulation 1997;96:2795–801.
14. White JW Jr. Relative significance of dietary sources of nitrate and
nitrite. J Agric Food Chem 1975;23:886–91.
15. Shapiro HM. Practical Flow Cytometry. 3rd ed. New York: Wiley-
Liss, Inc. 1995.
16. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive
detection of endothelial dysfunction in children and adults at risk of
atherosclerosis. Lancet 1992;340:1111–5.
17. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible
for flow-dependent dilatation of human peripheral conduit arteries in
vivo. Circulation 1995;91:1314–9.
18. Koh KK, Blum A, Hathaway L, et al. Vascular effects of estrogen and
vitamin E therapies in postmenopausal women. Circulation 1999;100:
1851–7.
19. Rees DD, Palmer RM, Hodson HF, Moncada S. A specific inhibitor
of nitric oxide formation from L-arginine attenuates endothelium-
dependent relaxation. Br J Pharmacol 1989;96:418–24.
20. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B
alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem
1995;270:14,214–9.
21. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases
275JACC Vol. 35, No. 2, 2000 Blum et al.
February 2000:271–6 L-arginine and Vascular Function in Postmenopausal Women
cytokine-induced endothelial activation: nitric oxide selectively reduces
endothelial expression of adhesion molecules and proinflammatory
cytokines. J Clin Invest 1995;96:60–8.
22. Peng HB, Rajavashisth TB, Libby P, Liao JK. Nitric oxide inhibits
macrophage-colony stimulating factor gene transcription in vascular
endothelial cells. J Biol Chem 1995;270:17,050–5.
23. Zeiher AM, Fisslhalter B, Schray-Utz B, Busse R. Nitric oxide
modulates the expression of monocyte chemoattractant protein 1 in
cultured human endothelial cells. Circ Res 1995;76:980–6.
24. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of
E-selectin, ICAM-1, and VCAM-1 are present in the supernatants of
cytokine activated cultured endothelial cells. Biochem Biophys Res
Commun 1992;187:584–9.
25. Newman W, Beall LD, Carson CW, et al. Soluble E-selectin is found
in supernatants of activated endothelial cells and is elevated in the
serum of patients with septic shock. J Immunol 1993;150:644–54.
26. Spertini O, Schleiffenbaum B, White-Owen C, Ruiz P Jr., Tedder TF.
ELISA for quantitation of L-selectin shed from leukocytes in vivo.
J Immunol Methods 1992;156:115–23.
27. Schleiffenbaum B, Spertini O, Tedder TF. Soluble L-selectin is
present in human plasma at high levels and retains functional activity.
J Cell Biol 1992;119:229–38.
28. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD. A form of
circulating ICAM-1 in human serum. J Immunol 1991;147:3788–93.
29. Nakai K, Itoh C, Kawazoe K, et al. Concentration of soluble vascular
cell adhesion molecule-1 (VCAM-1) correlated with expression of
VCAM-1 mRNA in the human atherosclerotic aorta. Coron Artery
Dis 1995;6:497–502.
30. Haught WH, Mansour M, Rothlein R, et al. Alterations in circulating
intercellular adhesion molecule-1 and L-selectin: further evidence for
chronic inflammation in ischemic heart disease. Am Heart J 1996;132:
1–8.
31. Peter K, Nawroth P, Conradt C, et al. Circulating vascular cell
adhesion molecule-1 correlates with the extent of human atheroscle-
rosis in contrast to circulating intercellular adhesion molecule 1,
E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb
Vasc Biol 1997;17:505–12.
32. Koh KK, Bui MN, Mincemoyer R, Cannon RO III. Effects of
hormone therapy on inflammatory cell adhesion molecules in post-
menopausal healthy women. Am J Cardiol 1997;80:1505–7.
33. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral
L-arginine inhibits platelet aggregation but does not enhance
endothelium-dependent dilation in healthy young men. J Am Coll
Cardiol 1995;26:1054–61.
34. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide
synthase inhibitor: a novel marker of atherosclerosis. Circulation
1999;99:1141–6.
276 Blum et al. JACC Vol. 35, No. 2, 2000
L-arginine and Vascular Function in Postmenopausal Women February 2000:271–6
